01—Abstract
Summary
Summary of the 8-K filed November 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Oracle's 8-K reports two governance events, neither of which includes financial results or guidance.
First, the Board unanimously elected Stephen Rusckowski as a director effective November 18, 2025, and increased the Board size to 14. He is a former CEO and President of Quest Diagnostics (2012 to 2022) and former Chair of Quest's board, and he previously led Philips Healthcare. He will receive a pro-rated annual equity grant of RSUs under the 1993 Directors' Stock Plan, which vest on the first anniversary of grant, plus standard non-employee director cash compensation.
He also signed Oracle's standard indemnification agreement. Oracle said his healthcare and technology experience will help it serve patients and providers through Oracle Health. Second, at the November 18, 2025 Annual Meeting, stockholders re-elected all 13 nominees, including Chairman Larry Ellison and CEO-level directors Safra Catz and Clayton Magouyrk, approved the advisory say-on-pay proposal, and ratified Ernst & Young as auditor for fiscal year ending May 31, 2026.
Support levels were mixed. Bruce Chizen drew the most opposition, with about 560.9 million votes withheld (roughly 24%a of votes cast for him), and Ablo, Berg, Boskin, Conrades, Henley, Seligman, and Chizen all had withheld totals above 180 million. Say-on-pay passed, with about 1.92 billion votes for and 423.8 million against, or roughly 82% approval of votes cast for or against.
For investors, this filing is routine in substance. The board expansion and new director add healthcare-sector perspective but do not change Oracle's near-term financial profile.
The shareholder vote results are the more notable signal. The sizable withhold votes for several directors and the roughly 18%b against vote on executive pay are worth monitoring for proxy-advisor or governance concerns in future proxy seasons, but the filing does not explain the reasons for them.
02—Key points
Key Highlights
- Stephen Rusckowski, former CEO of Quest Diagnostics, was elected to Oracle's Board effective November 18, 2025, and the Board was expanded to 14 members.
- Rusckowski's director compensation includes a pro-rated RSU grant under the 1993 Directors' Stock Plan that vests on the first anniversary of grant, plus standard cash retainer, and he received Oracle's standard indemnification agreement.
- All 13 director nominees were re-elected at the November 18, 2025 Annual Meeting, with terms running until the 2026 meeting.
- Bruce Chizen received the largest withhold vote, about 560.9 million shares, roughly 24% of votes cast for him, the most significant dissent among the nominees.
- The advisory say-on-pay proposal passed with about 1.92 billion votes for and 423.8 million against, roughly 82% approval of votes cast for or against.
- Stockholders ratified Ernst & Young LLP as independent auditor for fiscal year ending May 31, 2026, with about 2.55 billion votes for and 63.4 million against.
- The filing contains no financial results, guidance, or material financial impact, so it is primarily a governance update.
03—Questions
Frequently Asked Questions
Does the election of Stephen Rusckowski have any material financial impact on Oracle?
The filing does not indicate any material financial impact. His compensation is the standard non-employee director package, including a pro-rated RSU grant and cash retainer, and the filing does not disclose dollar amounts. The board expansion to 14 members is a governance change rather than a financial one.
What does Rusckowski bring to Oracle's board?
He has led healthcare organizations, including serving as CEO and President of Quest Diagnostics from 2012 to 2022 and as Chair of its board through March 2023, and he previously was CEO of Philips Healthcare. Oracle stated that his experience will help Oracle Health serve patients and healthcare providers. He currently sits on the supervisory board of Qiagen N.V. and the board of Baxter International.
Why did Bruce Chizen receive so many withhold votes, and should investors be concerned?
The filing reports about 560.9 million votes withheld for Chizen, roughly 24% of votes cast for him, but it does not give the reasons. He was still re-elected. Investors may want to check Oracle's proxy statement and any proxy-advisor commentary for context, since significant withhold votes can signal governance concerns but do not by themselves indicate a problem.
How did stockholders vote on executive compensation?
The advisory say-on-pay proposal passed, with about 1,922.9 million votes for, 423.8 million against, and 3.6 million abstaining. That is roughly 82% support among votes cast for or against. The result is advisory and non-binding, but about 18% opposition is a meaningful level of dissent that boards often respond to in later compensation decisions.
Did Oracle change its auditor?
No. Stockholders ratified the continued appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending May 31, 2026. The vote was 2,549.8 million for, 63.4 million against, and 2.8 million abstaining.
04—Continue